Clinical Trial Update: A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study of Velcade (bortezomib) in relapsed or refractory follicular lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Lymphoma Study Association | Conditions: Follicular Lymphoma | Phase 2 | Status: TERMINATED